Your browser doesn't support javascript.
loading
Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.
Perros, P; Zarkovic, M P; Panagiotou, G C; Azzolini, C; Ayvaz, G; Baldeschi, L; Bartalena, L; Boschi, A M; Nardi, M; Brix, T H; Covelli, D; Daumerie, C; Eckstein, A K; Fichter, N; Ciric, S; Hegedüs, L; Kahaly, G J; Konuk, O; Lareida, J J; Okosieme, O E; Leo, M; Mathiopoulou, L; Clarke, L; Menconi, F; Morris, D S; Orgiazzi, J; Pitz, S; Salvi, M; Muller, I; Knezevic, M; Wiersinga, W M; Currò, N; Dayan, C M; Marcocci, C; Marinò, M; Möller, L; Pearce, S H; Törüner, F; Bernard, M.
Afiliación
  • Perros P; Department of Endocrinology, Level 6, Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, Tyne, UK. petros.perros@ncl.ac.uk.
  • Zarkovic MP; Faculty of Medicine, University of Belgrade, Dr Subotica 8, Belgrade, Serbia.
  • Panagiotou GC; Department of Endocrinology, Level 6, Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, Tyne, UK.
  • Azzolini C; Department of Medicine and Surgery, Section of Ophthalmology, School of Medicine, University of Insubria, Via Guicciardini 9, 21100, Varese, Italy.
  • Ayvaz G; Department of Endocrinology, Yüksek Ihtisas University Ankara Koru Hastanesi, 1450. Sk. No:13, Kizilirmak, 06510, Çankaya, Ankara, Turkey.
  • Baldeschi L; Department of Ophthalmology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Bartalena L; Endocrine Unit, University of Insubria, Ospedale di Circolo, Viale Borri, 57 21100, Varese, Italy.
  • Boschi AM; Department of Ophthalmology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Nardi M; Dipartimento di Patologia Chirurgica Medica, Molecolare e Dell'Area Critica, Università di Pisa, Pisa, Italy.
  • Brix TH; Department of Endocrinology and Metabolism, Odense University Hospital, 5000, Odense, Denmark.
  • Covelli D; Graves' Orbitopathy Center, Endocrinology, Fondazione IRCCS Cà Granda, University of Milan, via Sforza, 35 - I-20122, Milan, Italy.
  • Daumerie C; Department of Endocrinology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Eckstein AK; Department of Ophthalmology, University of Duisburg-Essen, 45122, Essen, Germany.
  • Fichter N; Interdisciplinary Centre for Graves' Orbitopathy, 4600, Olten, Switzerland.
  • Ciric S; Clinic of Endocrinology, Clinical Centre of Serbia, Belgrade, Serbia.
  • Hegedüs L; Department of Endocrinology and Metabolism, Odense University Hospital, 5000, Odense, Denmark.
  • Kahaly GJ; Department of Medicine I, Johannes Gutenberg University Medical Center, 55101, Mainz, Germany.
  • Konuk O; Department of Ophthalmology, Faculty of Medicine, Gazi University, Besevler, Ankara, 06500, Turkey.
  • Lareida JJ; Interdisciplinary Centre for Graves' Orbitopathy, 4600, Olten, Switzerland.
  • Okosieme OE; Thyroid Research Group, Cardiff University School of Medicine, Cardiff, UK.
  • Leo M; Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Mathiopoulou L; Department of Endocrinology, Level 6, Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, Tyne, UK.
  • Clarke L; Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Menconi F; Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Morris DS; Cardiff Eye Unit, University Hospital of Wales, Cardiff, UK.
  • Orgiazzi J; Department of Endocrinology, Centre Hospitalier Lyon-Sud, Lyon, France.
  • Pitz S; Orbital Center, Ophthalmic Clinic, Bürger Hospital, Frankfurt, Germany.
  • Salvi M; Graves' Orbitopathy Center, Endocrinology, Fondazione IRCCS Cà Granda, University of Milan, via Sforza, 35 - I-20122, Milan, Italy.
  • Muller I; Graves' Orbitopathy Center, Endocrinology, Fondazione IRCCS Cà Granda, University of Milan, via Sforza, 35 - I-20122, Milan, Italy.
  • Knezevic M; Medical School, Clinic for Ophthalmology, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia.
  • Wiersinga WM; Department of Endocrinology, Academic Medical Center, Amsterdam, Netherlands.
  • Currò N; Department of Surgery, Ophthalmology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Dayan CM; Thyroid Research Group, Cardiff University School of Medicine, Cardiff, UK.
  • Marcocci C; Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Marinò M; Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Möller L; Interdisciplinary Centre for Graves' Orbitopathy, 4600, Olten, Switzerland.
  • Pearce SH; Department of Endocrinology, Level 6, Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, Tyne, UK.
  • Törüner F; Department of Endocrinology, Faculty of Medicine, Gazi University, Besevler, Ankara, 06500, Turkey.
  • Bernard M; Neuro-Ophthalmology Outpatient Clinics, GHE-Hospices Civils de Lyon and Lyon 1 University, Lyon, France.
J Endocrinol Invest ; 43(12): 1717-1722, 2020 Dec.
Article en En | MEDLINE | ID: mdl-32474767
PURPOSE: Patients with Graves' orbitopathy can present with asymmetric disease. The aim of this study was to identify clinical characteristics that distinguish asymmetric from unilateral and symmetric Graves' orbitopathy. METHODS: This was a multi-centre study of new referrals to 13 European Group on Graves' Orbitopathy (EUGOGO) tertiary centres. New patients presenting over a 4 month period with a diagnosis of Graves' orbitopathy were included. Patient demographics were collected and a clinical examination was performed based on a previously published protocol. Patients were categorized as having asymmetric, symmetric, and unilateral Graves' orbitopathy. The distribution of clinical characteristics among the three groups was documented. RESULTS: The asymmetric group (n = 83), was older than the symmetric (n = 157) group [mean age 50.9 years (SD 13.9) vs 45.8 (SD 13.5), p = 0.019], had a lower female to male ratio than the symmetric and unilateral (n = 29) groups (1.6 vs 5.0 vs 8.7, p < 0.001), had more active disease than the symmetric and unilateral groups [mean linical Activity Score 3.0 (SD 1.6) vs 1.7 (SD 1.7), p < 0.001 vs 1.3 (SD 1.4), p < 0.001] and significantly more severe disease than the symmetric and unilateral groups, as measured by the Total Eye Score [mean 8.8 (SD 6.6) vs 5.3 (SD 4.4), p < 0.001, vs 2.7 (SD 2.1), p < 0.001]. CONCLUSION: Older age, lower female to male ratio, more severe, and more active disease cluster around asymmetric Graves' orbitopathy. Asymmetry appears to be a marker of more severe and more active disease than other presentations. This simple clinical parameter present at first presentation to tertiary centres may be valuable to clinicians who manage such patients.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oftalmopatía de Graves Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Endocrinol Invest Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oftalmopatía de Graves Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Endocrinol Invest Año: 2020 Tipo del documento: Article